Business Wire

Veristat Supported Marketing Applications for 12% of all FDA Novel Drug Approvals in 2021

Share

Veristat, a scientific-minded global clinical research organization (CRO), announced today that the Company supported clients in preparing marketing applications for 12% of the 2021 U.S. Food and Drug Administration (FDA) novel drug approvals. This surpasses the number of approvals supported in 2020. In 2021, the FDA approved 50 novel drugs, defined as New Molecular Entities (NMEs).

Veristat’s bold thinking, focus, and extensive experience supporting complex drug development in rare and ultra-rare diseases significantly impacted these transformational medicines designed for patients with few or no treatment options. The work of Veristat’s innovative regulatory, statistical, and medical writing experts was vital in preparing six of these NME New Drug Applications (NDAs) and Biologics License Applications (BLAs). Veristat also prepared one supplemental New Drug Application (sNDA) for a non-NME that received FDA approval and one Marketing Authorization Application (MAA) that received approval in Europe. All but one of these 2021 approvals are for rare diseases.

“Throughout 2021 and in collaboration with our sponsors, we were able to successfully overcome the many scientific, regulatory, and data challenges that novel therapy research presents. We are grateful for the opportunity to have collaborated with our clients to achieve their goals and to bring novel therapies to patients,” stated Patrick Flanagan, Chief Executive Officer at Veristat. “Despite the remarkable advances in recent years in the understanding of rare diseases and in the approval of medicines to treat them, many unmet needs of patients remain. Our work continues with efforts such as the expansion of decentralized clinical trials that bring clinical research closer to the patient’s home.”

Since the Company’s founding 27 years ago, Veristat has collaborated with hundreds of biopharmaceutical clients around the globe to prepare more than 140 marketing applications. More than 65% of these marketing applications for rare and ultra-rare diseases. While a large majority of these engagements were with the FDA, the Company also holds an impressive track record with Health Canada and the European Medicines Agency (EMA). And with the recent acquisition of European regulatory consultancy agency Drug Development and Regulation (DDR) — and with it Dr. Xavier Luria, former Head of Safety and Efficacy of Medicines at the EMA— Veristat can provide clients with a deep understanding of the EMA and other key regulators.

“Advancing complex therapies for challenging diseases is what motivates us every day,” said John Balser, Ph.D., President & Chief Statistical Officer at Veristat. “It is gratifying to know that our scientific-minded teams were instrumental in helping clients prepare these marketing applications for therapies that received approval, thereby helping to improve the lives of patients and their families. A large part of our success, and what distinguishes Veristat, is the ability of our multi-disciplinary project teams to draw the appropriate connections amongst the fundamental constructs of the science, the practical and operational requirements of the clinical program, and the regulatory pathway, that combined provide the evidentiary basis for product approval. In 2022, Veristat will build upon our world-class biometrics, clinical, and regulatory capabilities to successfully tackle challenging diseases and meet the goals of our clients.”

About Veristat

Veristat, a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 27 years of experience in clinical trial planning and execution, Veristat is equipped to support any development program.

Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. Every day, we apply this knowledge base to solve any clinical program's challenges, from the simplest to the most complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Veristat Contact:
Lauren L. Brennan, Director of Marketing
media@veristat.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enviva Announces Public Offering of Common Stock20.1.2022 00:38:00 EET | Press release

Enviva Inc. (NYSE: EVA) (“Enviva,” “we,” “us,” or “our”) today announced that it has commenced an underwritten public offering (the “Offering”) of 4,300,000 common shares. Enviva expects to grant the underwriters an option to purchase up to an additional 645,000 common shares from Enviva at the issue price of the Offering. Enviva intends to use the net proceeds of the Offering for general corporate purposes, including pre-funding a portion of its capital expenditures related to ongoing development projects, and the temporary repayment of debt. Goldman Sachs & Co. LLC, Citigroup Global Markets Inc., J.P. Morgan Securities LLC, Barclays Capital Inc., BMO Capital Markets Corp., HSBC Securities (USA) Inc., RBC Capital Markets, LLC, and Truist Securities are acting as joint book-running managers for the Offering. Loop Capital Markets LLC, Raymond James & Associates, Inc., and USCA Securities LLC are acting as co-managers for the Offering. The Offering is being made pursuant to an effective

Enviva Announces MOU With U.S. Customer, Provides Updates to Business and Sales Pipeline, and Accelerates Capacity Expansions20.1.2022 00:33:00 EET | Press release

Enviva Inc. (NYSE: EVA) (“Enviva,” “we,” “us,” or “our”) today provided a business update announcing a memorandum of understanding (“MOU”) with Enviva’s first U.S.-based customer, and detailing plans to significantly accelerate its capital expansion timeline due to recent commercial momentum with power and heat generators and with industrials in hard-to-abate sectors. The business update also included preliminary 2021 financial results. Highlights: Announced plans to accelerate doubling of production capacity over the next five years, including bringing forward plans for a third plant in the Pascagoula, Mississippi cluster as well as additional plants around Savannah, Georgia and in the mid-Atlantic regions, with capability to build and commission two plants per year, up from one per year Signed MOU with Enviva’s first U.S.-based customer, to develop a supply chain strategy to support the customer’s biofuel refining facilities in the Southeast U.S. and potentially California Announced

DXC Technology Expands Global Partnership with ServiceNow to Accelerate Enterprise Service Management and Operational Transformation, Underpinned by DXC Platform X™20.1.2022 00:00:00 EET | Press release

DXC Technology (NYSE: DXC), a leading Fortune 500 global technology services company, announced the formation of a new global DXC ServiceNow Strategic Business Group to deliver market-leading, cost-efficient, resilient technology services that transform enterprise service operations, built on DXC Platform X TM. DXC has named ServiceNow the preferred workflow partner for DXC Platform X, a data-driven, intelligent automation platform that helps detect, prevent and address issues before they happen with resilient, self-healing IT estates. NelsonHall has named DXC Platform X as a “Leader in Cognitive & Self-Healing IT Infrastructure Management,” reflecting DXC’s ability to deliver immediate benefits through automation while meeting customer requirements for their future operating models. “For our customers, it’s about modernizing and automating their IT estates to achieve a state of ‘silent operations,’ saving time, money and letting customers focus on what’s most important --- running the

Dole Affiliate Receives Social Responsibility in Action Award in Costa Rica19.1.2022 20:57:00 EET | Press release

The American-Costa Rican Chamber of Commerce (AmCham) recognized Dole through its daughter company, Standard Fruit Company de Costa Rica S.A., with the Social Responsibility in Action Award in the Employees Category for their project "De la Mano con Dole" — which loosely translates to "Hand-in-Hand with Dole". This year marks the 25th anniversary of the award which was given December 8, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220119005875/en/ From left: Sandra Lima, Dole Corporate Social Responsibility Senior Manager; Steve Aronson, Horizonte Positivo Board Member; Ana Cristina Obregón, Dole Logistics & Planning Senior Director; Renato Acuña, President of Dole Fresh Fruit Latin America; Gisela Sánchez, AmCham Board President; and Marco Tulio Escobedo, Dole Human Resources Director (Photo: Business Wire) The Hand-in-Hand with Dole project is an initiative that works towards positively impacting the social develop

Q4 Inc. Announces Appointment of Julie Silcock, Investment Banking Veteran, to Board of Directors19.1.2022 20:48:00 EET | Press release

Q4 Inc. (TSX: QFOR) (“Q4” or “the Company”), a leading capital markets communications platform, today announced the appointment of Julie Silcock, currently a Senior Advisor at CDX Advisors, bringing 35 years of Capital Markets and M&A experience, to Q4’s Board of Directors, effective immediately. As a Senior Advisor at CDX Advisors, a tech-enabled investment bank, Ms. Silcock is involved in strategic advisory M&A and capital raising activities primarily for growth-oriented companies in the Southwest. Ms. Silcock previously served as Co-Head of Southwest Investment Banking at Houlihan Lokey and, prior to that, founded and acted as Head of Southwest Investment Banking at Citigroup. Ms. Silcock earned her M.B.A. from Stanford Graduate School of Business and holds a B.A. degree from Princeton University. She currently also serves on the boards of MoneyGram International, Overseas Shipholding Group, Inc., a crude oil and petroleum shipping company, JC Skincare, a privately held beauty compa

Alation Launches “Data Radicals” Podcast with Revolutionary Insights Transforming the Way We Use Data19.1.2022 17:00:00 EET | Press release

Alation Inc., the leader in enterprise data intelligence solutions, today announced the debut of its podcast, “Data Radicals.” Hosted by Satyen Sangani, CEO and co-founder of Alation, “Data Radicals” is a show for business, data, and technology enthusiasts who seek to enable individuals and organizations to use data in powerful ways. The podcast kicks off today, with the first 5 episodes available online, as well as Apple Podcasts, Spotify, and anywhere podcasts are available. “Data Radicals” is for anyone interested in how data, science, and technology can help solve the world’s most pressing problems. Episodes explore how data leaders and academics are driving data culture and the role they play in changing how people think and work. The podcast leaves listeners with an understanding of how to facilitate data-driven decision-making and data literacy at all levels of an organization. “The launch of ‘Data Radicals’ gives business leaders, entrepreneurs, and those of us passionate about

Protegrity Partners With Google Cloud to Support BigQuery Remote Functions19.1.2022 17:00:00 EET | Press release

Protegrity, a global leader in data security, today announced it has partnered with Google Cloud to support the upcoming release of BigQuery remote functions. First announced at Google Cloud Next ‘21 in October, BigQuery remote functions offer Google Cloud customers the ability to extend BigQuery with their own external code. With support for remote functions, Protegrity adds an additional layer of data protection, while enabling customers to deliver faster, more robust analysis through Google Cloud BigQuery. Protegrity’s partnership with Google Cloud lays a strong foundation to deliver de-identified data sets across many Google Cloud services. In addition to its support for Google Cloud remote functions, Protegrity also announced the availability of the Cloud API for Google Cloud, a serverless API that can be used to integrate data protection into cloud services and ETL workflows, as well as the Snowflake Protector on Google Cloud. “Through our partnership with Google Cloud, one of th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom